Open-label safety study in adults and adolescents with haemophilia A with and without FVIII inhibitors switching directly from emicizumab prophylaxis to NNC0365-3769 (Mim8) prophylaxis.

Status

Ongoing, recruiting

Phase

Therapeutic confirmatory (Phase III)

Sponsor

Novo Nordisk A/S

Enrolment target

24

Start

20 Jun 2023

Age 18 Years to any · Sex: All

• —

  Belgium
• —

  Spain
• —

  France
• —

  Austria
• —

  Italy
• —

  Germany